Breast Cancer Genomic Profiling Reveals Clues to Treatment Resistance

Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers.

More than 40,000 American women will die from breast cancer this year – approximately 80 percent of them because their tumors are resistant to anti-estrogen therapy and have metastasized, or spread to other parts of their bodies.

Now researchers at Vanderbilt University Medical Center have used tumor genomic profiling to identify “potentially druggable” changes in breast cancers that are positive for the estrogen …
Cancers – Healthcanal.com

Leave a Reply

Your email address will not be published. Required fields are marked *

*